BR9912241A - Derivados de imidazol com substituição bifenilsulfonila, processos para a sua preparação, seu emprego como medicamento ou diagnóstico - Google Patents

Derivados de imidazol com substituição bifenilsulfonila, processos para a sua preparação, seu emprego como medicamento ou diagnóstico

Info

Publication number
BR9912241A
BR9912241A BR9912241-3A BR9912241A BR9912241A BR 9912241 A BR9912241 A BR 9912241A BR 9912241 A BR9912241 A BR 9912241A BR 9912241 A BR9912241 A BR 9912241A
Authority
BR
Brazil
Prior art keywords
processes
diagnosis
medicine
preparation
compounds
Prior art date
Application number
BR9912241-3A
Other languages
English (en)
Inventor
Heinz Werner Kleemann
Hans Jochen Lang
Jan-Robert Schwark
Stefan Petry
Andreas Weichert
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9912241A publication Critical patent/BR9912241A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE IMIDAZOL COM SUBSTITUIçãO BIFENILSULFONILA, PROCESSOS PARA A SUA PREPARAçãO, SEU EMPREGO COMO MEDICAMENTO OU DIAGNóSTICO"<D>. A invenção refere-se a compostos da fórmula (I), nos quais os símbolos têm os significados indicados na especificação. Os compostos de acordo com a invenção mostram propriedades antiarrítmicas dramáticas e contêm um composto cardioprotetor. Eles podem inibir preventivamente ou reduzir fortemente processos patofisiológicos na ocorrência de distúrbios isquêmicos, especialmente arritmia cardíaca isquêmica. Tais compostos também mostram uma forte inibição sobre a proliferação das células.
BR9912241-3A 1998-07-18 1999-07-10 Derivados de imidazol com substituição bifenilsulfonila, processos para a sua preparação, seu emprego como medicamento ou diagnóstico BR9912241A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19832428A DE19832428A1 (de) 1998-07-18 1998-07-18 Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP1999/004887 WO2000003996A1 (de) 1998-07-18 1999-07-10 Imidazolderivate mit biphenylsulfonylsubstitution, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum

Publications (1)

Publication Number Publication Date
BR9912241A true BR9912241A (pt) 2001-04-10

Family

ID=7874574

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912241-3A BR9912241A (pt) 1998-07-18 1999-07-10 Derivados de imidazol com substituição bifenilsulfonila, processos para a sua preparação, seu emprego como medicamento ou diagnóstico

Country Status (19)

Country Link
US (1) US6369236B1 (pt)
EP (1) EP1097141B1 (pt)
JP (1) JP4567885B2 (pt)
KR (1) KR20010071957A (pt)
CN (1) CN1211370C (pt)
AR (1) AR019405A1 (pt)
AT (1) ATE362920T1 (pt)
AU (1) AU764438B2 (pt)
BR (1) BR9912241A (pt)
CA (1) CA2338059A1 (pt)
DE (2) DE19832428A1 (pt)
HK (1) HK1038743A1 (pt)
HU (1) HUP0102607A3 (pt)
ID (1) ID27774A (pt)
PL (1) PL345585A1 (pt)
RU (1) RU2246488C2 (pt)
TR (1) TR200100134T2 (pt)
WO (1) WO2000003996A1 (pt)
ZA (1) ZA200100278B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832428A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
CA2691662A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag Imidazole derivatives as ccr2 receptor antagonists
JP5395905B2 (ja) 2008-09-02 2014-01-22 エルダー・ファーマシューティカルズ・リミテッド 抗炎症化合物
KR101044953B1 (ko) * 2009-01-07 2011-06-29 (주) 인우 코퍼레이션 이중분사노즐을 이용한 악취제거 시스템
CN106459105B (zh) * 2014-06-23 2021-05-07 日产化学工业株式会社 包含磺酰基键的硅烷化合物的制造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
TW215434B (pt) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716882B1 (fr) 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
CN1309645A (zh) 2001-08-22
EP1097141A1 (de) 2001-05-09
KR20010071957A (ko) 2001-07-31
AU5280799A (en) 2000-02-07
CN1211370C (zh) 2005-07-20
HUP0102607A2 (hu) 2002-03-28
RU2246488C2 (ru) 2005-02-20
JP4567885B2 (ja) 2010-10-20
CA2338059A1 (en) 2000-01-27
ID27774A (id) 2001-04-26
AR019405A1 (es) 2002-02-20
PL345585A1 (en) 2001-12-17
HUP0102607A3 (en) 2002-05-28
JP2002520399A (ja) 2002-07-09
ATE362920T1 (de) 2007-06-15
WO2000003996A1 (de) 2000-01-27
EP1097141B1 (de) 2007-05-23
ZA200100278B (en) 2001-08-06
US6369236B1 (en) 2002-04-09
HK1038743A1 (en) 2002-03-28
DE19832428A1 (de) 2000-01-20
AU764438B2 (en) 2003-08-21
DE59914347D1 (de) 2007-07-05
TR200100134T2 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
AU554125B2 (en) 4(aryl-alkyl)imidazole derivatives
BR0011938A (pt) Benzenocarbonamidas substituìdas por indanila, processos para a sua preparação, seu emprego como medicamento bem como preparados farmacêuticos contendo as mesmas
BR9912241A (pt) Derivados de imidazol com substituição bifenilsulfonila, processos para a sua preparação, seu emprego como medicamento ou diagnóstico
BRPI9915985B8 (pt) 2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas
BR9710955A (pt) Compostos de extrato de cacau e métodos para a produção e uso dos mesmos
BR0014804A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
EP0380157B1 (en) Wound healing powder
DE68906609D1 (de) Dopamin-vorlaeufer.
KR950700314A (ko) 루이스형 당쇄 유도체(Lewis-type sugar chain derivative)
BR0016678A (pt) Composto, formulação farmacêutica, uso de um composto, método para profilaxia ou tratamento de uma arritmia, e, processo para preparação de um composto
BR9909086A (pt) Derivados de piperidinila e n-amidinopiperidinila
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BR9907667A (pt) Bifenilsulfonilcianamidas, processos para a sua preparação e seu emprego como medicamento
BR0312702A (pt) Derivados de 3-guanidinocarbonil-1-heteroaril-pirrol, processo de preparação e intermediários desse processo, seu uso como medicamentos e composições farmacêuticas compreendendo os mesmos
EP0199117A2 (en) New therapeutical use of phosphocreatine
BR9912139A (pt) Derivados de imidazol com substituição bifenilsulfonila processo para sua preparação seu emprego como medicamento ou diagnóstico, assim como medicamento contendo-o
Gabor et al. Antibacterial effect of fisetin and fisetinidin
BR0312701A (pt) Derivados de 3-guanidinocarbonil-1-hete-roaril-indol, processo de preparação, seu uso como medicamentos e composições farmacêuticas os compreendendo
KR920700627A (ko) 치료제로서 1-페닐-2-아미노에탄올 유도체의 신규한 용도
NO961521L (no) Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner
BR0012329A (pt) Derivados de benzofurano
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
US6723751B1 (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylpenyl)ethyl)benzamide
BR0010821A (pt) Derivados de benzenossulfonamidas substituìda com cinamoilaminoalquila
US2676961A (en) Procaine-penicillin preparation

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 23/66, C07D 233/70, C07D 233/88, A61K 31/4164, A61P 9/00, A61P 9/06, A61P9/10, A61P 43/00

Ipc: C07D 233/66 (2008.04), C07D 233/70 (2008.04), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.